A Phase I dose-expansion study reported biomarker analysis that tracks AZD2811 in relapsed or refractory small-cell lung cancer, with the findings presented as evidence that biomarker monitoring can inform treatment efficacy in this setting. The report highlights work by Johnson, Fabbri, Ciardullo and colleagues and frames the analytics as a tool for more responsive clinical decision-making. The update reinforces a broader push in oncology for biomarker-guided learning loops in early trials, where direct efficacy signals can be hard to interpret and patient selection remains pivotal. For drug developers in small-cell lung cancer, the reported strategy could support dose and regimen optimization while clarifying which biomarker patterns align with clinical activity.